

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



COMMON SPLENDOR INTERNATIONAL HEALTH INDUSTRY GROUP LIMITED

(Incorporated in Bermuda with limited liability)

(Stock Code: 286)

APPOINTMENT OF EXECUTIVE DIRECTOR

The board of directors (the “**Board**”) of Common Splendor International Health Industry Group Limited (the “**Company**”) is pleased to announce that Mr Ye Jiong Xian (“**Mr Ye**”) has been appointed as the executive director of the Company with effect from 18 December 2015.

Mr Ye, 50, a chief surgeon, professor, doctor in management studies and doctoral advisor. He has nearly 30 years experience in the fields of clinical medicine, teaching, scientific research and management. He once served as senior executives in a number of top class Grade A hospitals. Mr Ye also held administrative positions with health care authorities for a number of years where he led the preparation work for setting up large general hospitals and won great awards in China. He was once sent to international universities such as the Harvard University to study where he accumulated rich experience in health care management. Mr Ye is currently the executive member of Logistics Management Special Committee under the Chinese Hospital Association (中國醫院協會醫院後勤管理專業委員會常務委員), the executive director of the Hospital Architecture System Research Branch under the Chinese Hospital Association (中國醫院協會醫院建築系統研究分會常務理事), the editorial board member of the book titled “Architecture and Equipment of Chinese Hospitals” (《中國醫院建築與裝備》) and the chief editor of the books titled “Practices in Setting up Hospitals” (《醫院籌建務實》) and “Norms for Etiquette of Medical Workers” (《醫務人員禮儀規範》).

Save as disclosed above, Mr Ye does not hold any other position in the Company nor did he hold any directorship in any listed company in the last three years. Mr Ye has entered into a service contract in respect of his appointment with a term of 3 years commencing from 18 December 2015. Mr Ye is entitled to a fixed annual remuneration of HKD460,000, which is determined with reference to the prevailing market conditions and his duties and responsibilities with the Company. Pursuant to the Company's Bye-Laws, Mr Ye is subject to retirement and be eligible for re-election at the forthcoming annual general meeting of the Company.

At the date of this announcement, neither Mr Ye nor any of his associates (as defined in the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited ("**Listing Rules**")) have any interests and short positions in the securities of the Company or any associated corporation of the Company within the meaning of Part XV of the Securities and Future Ordinance. Mr Ye does not have any relationships with any directors, senior management, substantial or controlling shareholders (as respectively defined in the Listing Rules) of the Company.

Save as disclosed above, the Company is not aware of other information in relation to the appointment of Mr Ye which is required to be disclosed pursuant to any requirements under Rule 13.51(2)(h) to (v) of the Listing Rules or any other matters that need to be brought to the attention of the shareholders of the Company.

The Board would like to extend its welcome to Mr Ye.

By order of the Board
**Common Splendor International
Health Industry Group Limited**
Cheung Wai Kuen
Chairman

Hong Kong, 18 December 2015

As at the date of this announcement, the Board of Directors of the Company comprises Mr Cheung Wai Kuen, Mr Cheng Hau Yan and Mr Ye Jiong Xian as executive Directors; Mr Lin Jiang as non-executive Director; and Mr Mai Yang Guang and Mr Yau Chi Ming as independent non-executive Directors.